Timing of dornase alfa inhalation for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Dentice, Ruth ^a   Elkins, Mark ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA; DEOXYRIBONUCLEASE I; DNASE1 PROTEIN, HUMAN;

ANTIBIOTIC THERAPY; BRONCHOSPASM; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COUGHING; CYSTIC FIBROSIS; DETERIORATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; EVENING DOSAGE; EXERCISE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HOSPITAL ADMISSION; HUMAN; LUNG CLEARANCE; LUNG FUNCTION; MORNING DOSAGE; MORTALITY; MUCOCILIARY CLEARANCE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL VOLUME; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; SPUTUM; SPUTUM VISCOSITY; SYSTEMATIC REVIEW; TIME; TOTAL LUNG CAPACITY; ADOLESCENT; ARTIFICIAL VENTILATION; CHILD; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; CHILD; COMBINED MODALITY THERAPY; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG ADMINISTRATION SCHEDULE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY THERAPY; TIME FACTORS; YOUNG ADULT;

EID: 84891709285     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007923.pub3     Document Type: Review

References (115)

1. Anderson P, Morton J. Evaluation of two different timings of Pulmozyme nebulisation in relation to chest physiotherapy in children with Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S74.
2. Bishop JR, Erskine OJ, Middleton PG. Timing of dornase alpha inhalation does not affect the efficacy of the airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. Journal of Physiotherapy 2011;57(4):223-9.
3. Middleton PG, Bishop J. Dornase alpha and physiotherapy - which should be first? A randomised, double-blind, placebo-controlled trial in CF adults [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):310. [MEDLINE: 97028227]
4. Fitzgerald DA, Hilton J, Jepson B, Smith L. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005;116(4):e549-54.
5. Fitzgerald DA, Hilton J, Smith L, Jepson B. Is dornase alfa (Pulmozyme) more effective before or after physiotherapy? A cross-over, randomised, placebo-controlled trial [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):309-10. [MEDLINE: 95392717]
6. van der Giessen L. Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis 2009;8(Suppl 1):S6-9.
7. van der Giessen LJ, Gosselink R, de Jongste JC, Hop WCJ, Tiddens HAWM. Timing of nebulisation of rhDNase and airway clearance techniques (ACT) in children with Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2005;4(Suppl):S97.
8. van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tiddens HA. RhDNase before airway clearance therapy improves airway patency in children with CF. Pediatric Pulmonology 2007;42(7):624-30.
9. van der Giessen L. Does the timing of inhaled dornase alfa matter?. Journal of Cystic Fibrosis 2009;8(Suppl 1):S6-9.
10. van der Giessen LJ, Gosselink R, Hop W, Tiddens H. RhDNase before or after going to sleep in children with cystic fibrosis? [abstract]. Journal of Cystic Fibrosis 2007;6(Suppl 1):S68.
11. van der Giessen LJ, Gosselink R, Hop WC, Tiddens HA. Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?. European Respiratory Journal 2007;30(4):763-8. [MEDLINE: 96279782]
12. Adde FV, Borges KTL, Hatanaka ACF, Nakaie CMA, Cardieri JMA, Oliveira RC, et al.Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2004;3(Suppl 1):S66.
13. Bakker EM, Volpi S, Salonini E, Mullinger B, Kroneberg P, Hop WCJ, et al.Efficacy of peripheral deposition of inhaled rhDNase in CF patients during a respiratory tract infection [abstract]. Journal of Cystic Fibrosis 2010;9 (Suppl 1):Abstract no: 239.
14. Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJ, Hop WC. Online supplement to 'Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation'. [online]. European Respiratory Journal 2011; Vol. 38, issue 6:1328-35.
15. Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJJCM, Hop WCJ, et al.Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. European Respiratory Journal 2011;38(6):1328-35.
16. Bakker M, Volpi S, Salonini E, van der Wiel E, Merkus P, Sintnicolaas C, et al.Peripheral versus central deposition of inhaled rhdnase in children with cystic fibrosis. Pediatric Pulmonology 2010;45(Suppl 33):306.
17. van den Beukel-Bakker M, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas C, Hop WC, et al.Samll airways response to doenase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients. Journal of Cytsic Fibrosis 2011;10 (Suppl 1):S19.
18. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. Proceedings of 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:80.
19. Ballmann M, von der Hardt H. Hyptertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis 2002;1(1):35-7.
20. Bollert FG, Paton JY, Marshall TG, Calvert J, Greening AP, Innes JA. Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group. European Respiratory Journal 1999;13(1):107-13.
21. Bollert FGE, McArthur DA, Greening AP, Innes JA. Targeted introduction of DNase in Scotland [abstract]. Pediatric Pulmonology 1995;20(Suppl 12):204.
22. Dodd ME, Moorcroft AJ, Haworth CS, Francis S, Miles J, Clayton N, et al.The effect of rhDNase on exercise performance and gas trapping in adults with cystic fibrosis: a randomised controlled trial [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:147.
23. Frederiksen B, Koch C, Hoiby N, Pressler T, Hansen A. Effect of aerosolised rhDnase (Pulmozyme®) on pulmonary infections in CF: an open randomised study [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):246. [MEDLINE: 95392717]
24. Frederiksen B, Pressler T, Hansen A, Koch C, Hoiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatrica 2006;95(9):1070-4. [MEDLINE: 96279782]
25. Eisenberg J. Clinical development of rhDNase in the United States [Developpement clinique de la rhDNase aux Etats-Unis]. Archives de Pediatrie 1995;2(7):674-8. [MEDLINE: 95392717]
26. Fuchs HJ, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B, et al.Aerosolised recombinant human DNase reduces pulmonary exacerbations and improves pulmonary function in patients with cystic fibrosis [abstract]. Proceedings of 36th Annual Conference on Chest Disease. 1993.
27. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al.Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine 1994;31(10):637-42.
28. Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni C, et al.A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. International Journal of Technology Assessment in Health Care 1996;12(1):52-61. [MEDLINE: 97028227]
29. Oster G, Huse DM, Lacer MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Annals of Pharmacotherapy 1995;29(5):459-64.
30. Ramsey B, For the Pulmozyme™ (rhDNase) Study Group. A summary of the results of the phase III multicenter clinical trial: Aerosol administration of recombinant human DNase reduces the risk of respiratory tract infections and improves pulmonary function in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1993;16(Suppl 9):152-3.
31. von der Schulenburg JM, Greiner W, von der Hardt H. Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis [Soziookonomische Evaluation des Einflusses von rhDNase auf die Kosten der Behandlung von Infektionen der Atemwege bei Patienten mit zystischer Fibrose]. Medizinische Klinik 1995;90(4):220-4.
32. Furuya ME, Lezana-Fernandez JL, Vargas MH, Hernandez-Sierra JF, Ramirez-Figueroa JL. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis. Archives of Medical Research 2001;32(1):30-4.
33. Grassemann H, Lax H, Tresler JW, Colin AA. Dornase alpha and exhaled NO in cystic fibrosis. Pediatric Pulmonology 2004;38(5):379-85.
34. Griese M, App EM, Derouix A, Burkert A, Schams A. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum. Pulmonary Pharmacology & Therapeutics 1997;10(1):21-7. [MEDLINE: 98035417]
35. Hagelberg M, Dooley MJ, Poole SG, Leung D, Bailey M, Finlayson F, et al.Direct dispensing of dornase alpha improves adherence and lung function in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S27. [MEDLINE: 96279782]
36. Heijerman HG, van Rossem RN, Bakker W. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients. Netherlands Journal of Medicine 1995;46(6):293-7.
37. Hjelte L, Eliasson H, Ljung M, Lagerstrand L. Improved gas exchange in patients with cystic fibrosis when treated with RhDNase [abstract]. Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:183.
38. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, et al.A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis Comment in: N Engl J Med 1992 Aug 20;327(8):571. New England Journal of Medicine 1992;326(12):812-5.
39. Lahiri T, Herrington H, Diehl S, Landrigan G. The effect of intranasal dornase alfa on chronic sinusitis in patients with cystic fibrosis: a pilot study [abstract]. Pediatric Pulmonology 2012;354:Abstract no: 354.
40. Laube BL, Auci RM, Shields DE, Christiansen D, Fuchs HJ, Rosenstein BJ. A randomized, placebo-controlled trial of the effect of recombinant human DNase (rhDNase) on the deposition homogeneity and mucociliary clearance of radioaerosol in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1993;16(Suppl 9):S13.5.
41. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;153(2):752-60.
42. Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respiratory Care 2005;50(11):1438-44.
43. Laube BL, Lin T, Geller D, Dalby R, Zeitlin P. Positive expiratory pressure alters aerosol distribution in CF [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):247.
44. Mainz J, Mentzel H, Scheider G, Riethmuller J, Schiller I, Ritschel C, et al.Double-blind, placebo-controlled pilot trial on sinonasal inhalation of dornase alfa in CF [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):305. [MEDLINE: 96279782]
45. Mainz J, Mentzel HJ, Schneider G, Riethmuller J, Schiller I, Ritschel C, et al.Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S27. [MEDLINE: 96279782]
46. Mainz JG, Schiller I, Koitschev A, Koitschev C, Riethmuller J, Wiedemann B, et al.Sinonasal inhalation of dornase alfa reduces rhinosinusitis symptoms in CF. Results of a DBPC-cross-over-study [abstract]. Journal of Cystic Fibrosis 2010, issue S23:Abstract no: 88.
47. Majaesic CM, Montgomery M, Jones R, King M. Reduction in sputum viscosity using high frequency chest compressions (HFCC) compared to conventional chest physiotherapy (CCP) [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):308.
48. Dab I, Malfroot A, Baran D, App EM, Coffiner M, Nagy AM. Randomized multicentric double blind study of safety and efficacy of nacystelyn® DPI versus placebo in rhDNase treated cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2000;161(3):A72.
49. Malfroot A, Dab I, Baran D, App EM, Coffiner M, Nagy AM. Randomised multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn® versus placebo in cystic fibrosis patients treated by rhDNase for at least 3 months [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:146.
50. Malfroot A, Dab I, Baran D, App EM, Coffiner M, Nagy AM. Randomized multicentric double blind study of tolerability and efficacy of a DPI Nacystelyn® versus placebo in cystic fibrosis patients treated by rhDnase for at least 3 months [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):244.
51. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996;110(4):889-95. [MEDLINE: 97028227]
52. McCoy K, for the Pulmozyme ® severe Lung Disease Study Group. rhDNase is well tolerated and effective in cystic fibrosis patients with severe obstructive lung disease [abstract]. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:L41.
53. Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65(1):51-6.
54. Minasian CC, Wallis C, Metcalfe C, Bush A. A crossover comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):301. [MEDLINE: 96279782]
55. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Aerosolized recombinant human DNase in cystic fibrosis patients younger than 5 years of age [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):278. [MEDLINE: 97028227]
56. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatric Pulmonology 2001;31(5):377-82.
57. Brody A, Molina PL, Klein JS, Campbell JD, Millard SP, Quan J. High-resolution CT is more sensitive to longitudinal decline in lung status in young children with CF than pulmonary function tests [abstract]. Pediatric Pulmonology 2003;36(Suppl 25):318.
58. Konstan MW, Wohl ME, McKenzie S, Sy J, Quan JM, Tiddens HA. A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme®) in cystic fibrosis patients aged 6-10 years with early lung disease [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):299-300.
59. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al.A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. Journal of Pediatrics 2001;139(6):813-20.
60. Robinson PJ. Dornase alfa in early cystic fibrosis lung disease. Pediatric Pulmonology 2002;34(3):237-41.
61. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, et al.Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. American Review of Respiratory Disease 1993;148(1):145-51.
62. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, et al.Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342(8865):199-202.
63. Ranasinha C, Empey D, Geddes D, Fuchs H, Hodson ME. A phase 2 double-blind placebo-controlled study of the pulmonary function and the safety of aerosolised recombinant human DNase in adults with stable stage cystic fibrosis [abstract]. Proceedings of the 11th International Cystic Fibrosis Congress; 1992; Dublin, Ireland. 1992:LBS5.
64. Shah PL, Dewar A, Hodson ME. Scanning electron microscopy of cystic fibrosis sputum [abstract]. European Respiratory Journal 1995;8(Suppl 19):574S.
65. Shah PL, Scott SF, Knight RA, Marriott C, Hodson ME. The effects of recombinant human DNase I on sputum DNA content [abstract]. European Respiratory Journal 1995;8(Suppl 19):574S.
66. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996;51(2):119-25. [MEDLINE: 96246620]
67. Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, et al.Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatric Pulmonology 2006;41(1):61-6.
68. Hemming AL, Robinson M, Moriarty C, Bautovich GJ, Bye PTP. Effect of short course of rhDNase on mucociliary clearance in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1997;23(Suppl 14):273.
69. Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PT. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatric Pulmonology 2000;30(1):16-24.
70. Robinson T, Goris ML, Bhise P, Sathi A, Zhu JH, Moss RB. Quantitative HRCT air trapping analysis in CF subjects with mild lung disease during a pulmozyme intervention study [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):298.
71. Robinson T, Leung AN, Northway WH, Blankenberg FG, Chan F, Bloch DA, et al.Composite CT/PFT score: An outcome measure which markedly improves sensitivity to change in early cystic fibrosis lung disease [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):298.
72. Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, et al.Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine 2003;168(5):588-93.
73. Shah PL, Kollnberger SD, Scott SF, Knight RA, Marriott C, Hodson ME. Recombinant Human DNase 1 depolymerises extracellular DNA in vivo [abstract]. Pediatric Pulmonology 1994;18(Suppl 10):210.
74. Shah PL, Scott SF, Marriott C, Hodson ME. Sputum rheology in severely ill patients with cystic fibrosis and the in vivo effects of recombinant human DNase1 [abstract]. Proceedings of the 19th European Cystic Fibrosis Conference; 1994 May 29-June 3; Paris, France. 1994:O84.
75. Hodson M. Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement [Etude multicentrique de la rhDNase dans les mucoviscidoses avec atteinte pulmonaire grave]. Archives de Pediatrie 1995;2(7):679-81. [MEDLINE: 95392718]
76. Shah PL, Bush A, Cannya J, Colin AA, Fuchs HJ, Geddes DM, et al.Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: A short-term, double-blind study followed by six months open-label treatment. European Respiratory Journal 1995;8(6):954-8.
77. Shah PL, Scott SF, Hodson ME. Report on a multicentre study using aerosolised recombinant human DNase 1 in the treatment of cystic fibrosis patients with severe pulmonary disease [abstract]. Pediatric Pulmonology 1993;16(Suppl 9):157-8.
78. Shah PL, Scott SF, Fuchs HJ, Geddes DM, Hodson ME. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax 1995;50(4):333-8. [MEDLINE: 96279782]
79. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine 1995;89(7):499-502. [MEDLINE: 96279782]
80. Smith A, Pepe M, Morlin G, Williams-Warren J, Ramsey B. Effect of rhDNase administration on sputum bacterial density [abstract]. Pediatric Pulmonology 1994;18(Suppl 10):S14.4.
81. Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care 2003;19(1):71-9.
82. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al.Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57(10):841-6.
83. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al.Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis [abstract]. Thorax 2001;56(Suppl 3):iii84.
84. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2002;166(3):352-5.
85. Suri R, Metcalfe C, Lees B, Flather M, Normand C, Thompson S, et al.A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with Cystic Fibrosis [abstract]. Thorax 2000;55:A75.
86. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al.Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-21.
87. Suri R, Metcalfe C, Wallis C, Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine 2007;101(2):254-60. [MEDLINE: 96279782]
88. Suri R, Metcalfe C, Wallis C, Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatric Pulmonology 2004;37(4):305-10.
89. Suri R, Wallis C, Bush A. Invivo use of hypertonic saline in CF [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):125-6.
90. Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, et al.A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment 2002;6(34):iii, 1-60.
91. Suri R, Wallis C, Metcalfe C, Thompson S, Bush A, Shute J. Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):281.
92. ten Berge M, van der Wiel E, Tiddens HAWM, Merkus PJFM, Hop WCJ, de Jongste JC. Clinical parameters of mucociliary clearance in infants with CF [abstract]. Netherlands Journal of Medicine 1999;54(Suppl):S3-4.
93. ten Berg M, van der Wiel E, Tiddens HAWM, Merkus PJFM, Hop WCJ, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. Journal of Cystic Fibrosis 2003;2(4):183-8.
94. Ungewitter A, Bertele-Harms RM, Harms HK. RhDNase, lung function and exercise in cystic fibrosis - a double-blind, placebo-controlled, cross-over study [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):306.
95. Ungewitter A, Bertele-Harms RM, Harms HK. RhDNase, lung function and exercise in cystic fibrosis - a double-blind, placebo-controlled, cross-over study [abstract]. Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:147.
96. Weck MB, Retsch-Bogart GZ, Scott CS. Efficacy of DNase in individual children using the N-of-1 study design [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):285.
97. Wilmott R, The DNase Multicenter Study Group, Genetech staff. A phase II, double blind, multicenter study of the safety and efficacy of aerosolized recombinant human DNase I (rhDNase) in hospitalized patients with CF experiencing acute pulmonary exacerbations [abstract]. Pediatric Pulmonology 1993;16(Suppl 9):154.
98. Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, et al.Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine 1996;153(6 Pt 1):1914-7. [MEDLINE: 96279782]
99. Wilson CJ, Robbins LJ, Murphy JM, Chang AB. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial. Pediatric Pulmonology 2007;42(12):1110-6. [MEDLINE: 96279782]
100. Bateman JR, Pavia D, Clark SW. The retention of lung secretions during the night in normal subjects. Clinical Science and Molecular Medicine. Supplement 1978;55(6):523-7.
101. Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, et al.An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. Journal of Cystic Fibrosis 2009;8(4):229-37.
102. Cooper PJ, Robertson CF, Hudson IL, Phelan PD. Variability of pulmonary function tests in cystic fibrosis. Pediatric Pulmonology 1990;8(1):16-22.
103. Cutting GR. Cystic fibrosis. In: Rimon DL, Connor JM, Pyeritz RE, Korf BR editor(s). Principles and Practice of Medical Genetics. 4th Edition. London: Harcourt, 2002:1561-606.
104. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Australian Journal of Physiotherapy 2009;55(2):129-33.
105. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
106. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
107. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
108. Jones AP, Wallis CE. Dornase alfa for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001127.pub2]
109. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA 1968;205(5):312-3.
110. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy 2003;83(8):713-21.
111. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al.Interpretative strategies for lung function tests. European Respiratory Journal 2005;26(5):948-68.
112. TGA Approved Product Information. Inhaltion Solution (dornase alfa). eMIMS last amendment 2005.
113. Shak S, Capon DJ, Hellmiss R, Marsters SA. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proceedings of the National Academy of Sciences USA 1990;87(23):9188-92.
114. Wolff RK, Dolovich MB, Obminski G, Newhouse MT. Effects of exercise and eucapnic hyperventilation on bronchial clearance in man. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology 1977;43(1):46-50.
115. Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD007923.pub2]